6-[(N-4-플루오로페닐)아미노]-7-클로로-5,8-퀴놀린디온의 in vivo 항진균 작용 평가

The Evaluation of in Vivo Antifungal Activities of 6-[(N-4-Fluorophenyl)amino]-7-Chloro-5,8-Quinolinedione

6-[(N-4-Fluorophenyl)amino]-7-chloro-5,8-quinolinedione(RCK3) was tested for antifungal activities, in vivo, against Candida albicans. RCK3 was compared with ketoconazole and fluconazole in the treatment of systemic infection with Candida albicans in normal mice. The therapeutic potential of RCK3 had been assessed by evaluating their activities (survival rate) against systemic infections in normal mice. RCK3 had ED50, 8.78 +/- 0.18mg/kg but ketoconazole and fluconazole had ED50, 8.00 +/- 0.73, 10.00 +/- 0.43mg/kg respectively. Intraperitoneally administered RCK3 at the ED50, 8.78mg/kg for 7 days and 14 days reduced Candida albicans colony count in the kidneys and livers as well as ketoconazole and fluconazole at these ED50, 8.00 and 10.00mg/kg. And administered RCK3 at the ED50 for 14 days improved survival rates better than ketoconazole.